Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

New treatment strategies have substantially changed the course of rheumatoid arthritis.
Many patients can achieve remission if the disease is recognised early and is treated …

Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …

Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor
antagonist, are approved (±methotrexate) in numerous countries throughout the world, for …

Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …

Although initially described as an anti-tumor mediator, tumor necrosis factor-alpha (TNF) is
generally considered as the master pro-inflammatory cytokine. It plays a crucial role in the …

The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1,
JAK2, JAK3, and TYK2 (tyrosine kinase-2). Each of these proteins contains a JAK homology …

Background Across European countries, differences exist in biosimilar policies, leading to
variations in uptake of biosimilars and divergences in savings all over Europe. Objectives …

Background The past decades have seen rapid advances in the treatment of rheumatoid
arthritis (RA). In particular, the introduction of biologic and targeted synthetic disease …